Share ownership Novavax, Inc.

NVAX

US6700024010

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:33:58 2026-03-16 pm EDT			5-day change	1st Jan Change
10.08 ^USD	-1.56%		-4.50%	+49.93%

Mar. 10	Novavax, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 03:40 PM
Mar. 03	Novavax, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 02:30 PM

Share class: Novavax, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	161,595,153	153,172,322 ( 94.79 %)	1,410,159 ( 0.8726 %)	94.79 %

Major shareholders: Novavax, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.52 %	15,470,365	9.52 %	157 M $
Shah Capital Management, Inc. 8.959 %	14,558,780	8.959 %	148 M $
BlackRock Advisors LLC 7.357 %	11,955,098	7.357 %	121 M $
STATE STREET CORPORATION 5.861 %	9,523,646	5.861 %	97 M $
Merrill Lynch International 5.102 %	8,290,665	5.102 %	84 M $
SANOFI 4.234 %	6,880,481	4.234 %	70 M $
D.E. Shaw & Co., Inc. 3.688 %	5,992,798	3.688 %	61 M $
UBS Financial Services, Inc. 2.818 %	4,578,523	2.818 %	46 M $
Millennium Management LLC 2.751 %	4,470,083	2.751 %	45 M $
Geode Capital Management LLC 2.29 %	3,721,323	2.29 %	38 M $
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	54.72%
Other	8.79%
State Street Corp.	5.86%
Sanofi	4.23%
Individuals	0.64%
Schweizerische Nationalbank	0.17%
Manulife Financial Corp.	0.04%
SEI Investments Co.	0.01%
Banco Bilbao Vizcaya Argentaria SA	0.01%
Unknown	25.53%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	59.87%
United Kingdom	7.9%
France	4.24%
Monaco	0.64%
Individuals	0.64%
Ireland	0.33%
Canada	0.32%
Switzerland	0.26%
Australia	0.05%
Spain	0.05%
China	0.04%
Japan	0.04%
Germany	0.03%
Norway	0.02%
Luxembourg	0.01%
Cayman Islands	0.01%
Singapore	0.01%
South Korea	0.01%
Denmark	0.01%

Based on 1000 largest holdings

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâ€™s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Employees

749

Sector

Biotechnology & Medical Research

More about the company